“(Cingulate) collectively decided that we wanted to put the minimum bid compliance issue with Nasdaq behind us and focus on some of the exciting catalysts ahead in the first quarter of next year,” said Thomas Dalton, the company's vice president of investor and public relations.KCK pharmaceutical company completes reverse stock split
“(Cingulate) collectively decided that we wanted to put the minimum bid compliance issue with Nasdaq behind us and focus on some of the exciting catalysts ahead in the first quarter of next year,” said Thomas Dalton, the company's vice president of investor and public relations.